Healthtech funding in Q1 2021
European Healthtech startup funding raised during Q1 2021.
In Q1 2021, 94 European Healthtech companies closed 95 funding rounds and raised €1.4B in equity funding (excluding debt and grants), up 57.7% versus Q1 2020. Debt rounds added €190M. UK led by capital raised, and Ada Ventures was the most active investor. Data as of 20 Nov 2026.
Equity funding
€1.4B
+57.7% vs Q1 2020 · excl. debt & grants · +€190M debt
Funding rounds
95
-12.8% vs Q1 2020
Companies
94
Top country
UK
Rank among sectors
#7
5.3% of sector funding
Debt financing
€190M
12.1% of total
Top-10 round share
58.5%
of disclosed capital
Rounds ≥ €100M
3
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, Q1 2021 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jan | €597M | 34 |
| Feb | €476M | 27 |
| Mar | €497M | 34 |
Top countries
by € raisedHealthtech — top countries by capital, Q1 2021 — interactive chart.
Data table
| Healthtech — top countries by capital, Q1 2021 | |
|---|---|
| UK | €482M |
| Germany | €254M |
| Israel | €188M |
| Spain | €172M |
| Denmark | €153M |
| Switzerland | €122M |
| France | €76M |
| Netherlands | €52M |
Stage mix
by € raisedHealthtech — stage mix, Q1 2021 — interactive chart.
Data table
| Healthtech — stage mix, Q1 2021 | |
|---|---|
| Other | €390M |
| Series C | €350M |
| Series B | €237M |
| Debt | €190M |
| Series A | €147M |
| Series D+ | €131M |
| Seed | €58M |
| Growth/Late | €58M |
| Crowdfunding | €6.7M |
| Early VC | €2.3M |
| Pre-Seed | €655k |
| Grant | €401k |
Exits & M&A
13 Acquisition · 1 IPO14 exits · €911M disclosed.
| Arvelle Therapeutics | Acquisition | Jan 2021 | €784M |
| Ginolis | Acquisition | Feb 2021 | €70M |
| MatTek | Acquisition | Mar 2021 | €57M |
Top deals
largest disclosed rounds in Q1 2021| Company | Stage | Date | Amount |
|---|---|---|---|
| Immunocore | Debt | Feb 2021 | €190M |
| Atai Life Sciences | Series D+ | Mar 2021 | €131M |
| IO Biotech | Series B | Jan 2021 | €127M |
| Melio | Series C | Jan 2021 | €90M |
| Evox Therapeutics | Series C | Feb 2021 | €80M |
| Monte Rosa | Series C | Mar 2021 | €80M |
| Immunocore | Series C | Jan 2021 | €62M |
| Eleva | Other | Jan 2021 | €60M |
| dariohealth | Growth/Late | Jan 2021 | €58M |
| MedAlliance | Other | Mar 2021 | €42M |
| Leyden Labs | Series A | Mar 2021 | €40M |
| PlusDental | Other | Mar 2021 | €35M |
| Ukko | Series B | Jan 2021 | €33M |
| Corwave | Series C | Jan 2021 | €33M |
| Ibex Medical Analytics | Series B | Mar 2021 | €32M |
Top investors
most active in Q1 2021, by deal count- Ada Ventures2 deals
- IBB Ventures2 deals
- Mercia Fund Managers2 deals
- Octopus Ventures2 deals
- 83North1 deals
- Accel1 deals
- Advanced MedTech Holdings (AMTH)1 deals
- Alma Mundi Ventures1 deals
- Almeda Ventures1 deals
- Apeiron Investment Group1 deals